IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulating therapeutic cancer vaccines, has announced its participation in two major investor conferences. The company will attend the Jefferies London Healthcare Conference on November 20, 2024, with one-on-one meetings led by CEO Mai-Britt Zocca and CFO Amy Sullivan. Additionally, CEO Mai-Britt Zocca will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2024, at 11:00 am ET. A webcast replay of the Piper Sandler presentation will be available on IO Biotech's website for 90 days.
IO Biotech (IOBT), una compagnia biofarmaceutica in fase clinica focalizzata sullo sviluppo di vaccini terapeutici anti-cancro che modulano il sistema immunitario, ha annunciato la sua partecipazione a due importanti conferenze per investitori. L'azienda parteciperà alla Jefferies London Healthcare Conference il 20 novembre 2024, con incontri individuali guidati dal CEO Mai-Britt Zocca e dal CFO Amy Sullivan. Inoltre, il CEO Mai-Britt Zocca prenderà parte a una discussione informale alla Piper Sandler 36th Annual Healthcare Conference a New York il 3 dicembre 2024, alle 11:00 ET. Una registrazione del webcast della presentazione di Piper Sandler sarà disponibile sul sito web di IO Biotech per 90 giorni.
IO Biotech (IOBT), una compañía biofarmacéutica en etapa clínica centrada en desarrollar vacunas terapéuticas contra el cáncer que modulan el sistema inmune, ha anunciado su participación en dos importantes conferencias de inversores. La empresa asistirá a la Jefferies London Healthcare Conference el 20 de noviembre de 2024, con reuniones individuales dirigidas por la CEO Mai-Britt Zocca y la CFO Amy Sullivan. Además, la CEO Mai-Britt Zocca participará en una charla informal en la Piper Sandler 36th Annual Healthcare Conference en Nueva York el 3 de diciembre de 2024, a las 11:00 am ET. Una repetición del webcast de la presentación de Piper Sandler estará disponible en el sitio web de IO Biotech durante 90 días.
IO Biotech (IOBT)는 면역 조절 암 치료 백신 개발에 주력하는 임상 단계의 생명공학 회사로, 두 개의 주요 투자자 회의에 참석할 것이라고 발표했습니다. 이 회사는 2024년 11월 20일 Jefferies London Healthcare Conference에 참석할 예정이며, CEO인 마이-브리트 조카(Mai-Britt Zocca)와 CFO인 에이미 서리반(Amy Sullivan)이 이끄는 일대일 회의가 진행됩니다. 추가로, CEO 마이-브리트 조카는 2024년 12월 3일 뉴욕에서 열리는Piper Sandler 제36회 연례 건강 관리 회의에서 11:00 am ET에 파이어사이드 차트에 참여할 예정입니다. Piper Sandler 발표의 웹캐스트 재생은 IO Biotech 웹사이트에서 90일 동안 이용 가능합니다.
IO Biotech (IOBT), une société bio-pharmaceutique en phase clinique spécialisée dans le développement de vaccins thérapeutiques contre le cancer modulant le système immunitaire, a annoncé sa participation à deux grandes conférences pour investisseurs. L'entreprise assistera à la Jefferies London Healthcare Conference le 20 novembre 2024, avec des réunions individuelles dirigées par la PDG Mai-Britt Zocca et la CFO Amy Sullivan. De plus, la PDG Mai-Britt Zocca participera à une discussion informelle lors de la Piper Sandler 36th Annual Healthcare Conference à New York le 3 décembre 2024, à 11h00 ET. Un replay du webinaire de la présentation Piper Sandler sera disponible sur le site Web d'IO Biotech pendant 90 jours.
IO Biotech (IOBT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von immunmodulierenden therapeutischen Krebsimpfstoffen konzentriert, hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 20. November 2024 an der Jefferies London Healthcare Conference teilnehmen, bei der individuelle Meetings unter der Leitung von CEO Mai-Britt Zocca und CFO Amy Sullivan stattfinden. Darüber hinaus wird CEO Mai-Britt Zocca an einem informellen Gespräch auf der Piper Sandler 36th Annual Healthcare Conference in New York am 3. Dezember 2024 um 11:00 Uhr ET teilnehmen. Eine Aufzeichnung des Webcasts der Piper Sandler-Präsentation wird für 90 Tage auf der Website von IO Biotech verfügbar sein.
- None.
- None.
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences:
Event: Jefferies London Healthcare Conference
Location: London
One-on-one meetings: Wednesday, November 20, 2024
Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO
Event: Piper Sandler 36th Annual Healthcare Conference
Location: New York, New York
Fireside chat: Tuesday, December 3, 2024 at 11:00 am ET
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1697959&tp_key=934ba9e309
A webcast replay of the Piper Sandler fireside chat will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation.
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Salutem
917-498-1967
Julie.Funesti@salutemcomms.com
FAQ
When is IO Biotech (IOBT) presenting at the Piper Sandler Healthcare Conference in 2024?
Which investor conferences will IO Biotech (IOBT) attend in late 2024?
How long will the Piper Sandler Conference webcast be available on IO Biotech's website?
Who will represent IO Biotech (IOBT) at the Jefferies London Healthcare Conference?
